Trials / Completed

CompletedNCT00006137

Pilot Study of Enalapril and Renal Function in Patients With IgA Nephropathy

Status: Completed
Phase: N/A
Study type: Interventional
Enrollment: 43 (planned)

Sponsor: National Center for Research Resources (NCRR) · NIH
Sex: All
Age: 13 Years – 60 Years
Healthy volunteers: Accepted

Summary

OBJECTIVES: I. Determine the most sensitive outcome measures (functional or morphological) of a progressive renal injury in patients with IgA nephropathy. II. Determine which of these patients are destined to progress to further injury in order to target them for therapy. III. Elucidate the determinants of progression in those patients who exhibit evidence of either increasing impairment of ultrafiltration capacity or ongoing destruction of nephrons.

Detailed description

PROTOCOL OUTLINE: Patients receive oral enalapril daily. Treatment continues for 5 years in the absence of unacceptable toxicity. Patients undergo renal function studies every 6-12 months for 5 years. Patients undergo renal biopsy at 36-48 months after study entry.

Conditions

IGA Glomerulonephritis

Interventions

Type	Name	Description
DRUG	enalapril

Timeline

Start date: 2000-05-01
First posted: 2000-08-04
Last updated: 2005-06-24

Source: ClinicalTrials.gov record NCT00006137. Inclusion in this directory is not an endorsement.